How to consider events occurring after the pre-specified observational period?

Stefan Hantel & Erich Bluhmki
In event driven trials investigating for example new drugs for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), the primary outcome variable is a composite endpoint of recurrent events (e.g., recurrent DVT, PE or VTE related mortality) observed during the pre-specified treatment[for full text, please go to the a.m. URL]